Current status of high dose chemotherapy in breast cancer.

S. Glück, D. Stewart

Research output: Contribution to journalReview articlepeer-review


To date, no definite answers are available to the initial question, whether or not HDCT and ASCT can improve quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment; applying drugs that are active breast cancer; comparing the experimental treatment to standard therapy; and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian Studies [6, 14] that are currently accruing patients, will contribute versus important information regarding the role of HDCT and ABMT for breast cancer.

Original languageEnglish (US)
Pages (from-to)30-32
Number of pages3
JournalPrzegla̧d lekarski
Volume57 Suppl 1
StatePublished - 2000

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Current status of high dose chemotherapy in breast cancer.'. Together they form a unique fingerprint.

Cite this